↓ Skip to main content

The effects of short-term fasting on tolerance to (neo) adjuvant chemotherapy in HER2-negative breast cancer patients: a randomized pilot study

Overview of attention for article published in BMC Cancer, October 2015
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • Among the highest-scoring outputs from this source (#42 of 9,009)
  • High Attention Score compared to outputs of the same age (97th percentile)
  • High Attention Score compared to outputs of the same age and source (98th percentile)

Mentioned by

news
9 news outlets
twitter
26 X users
patent
1 patent
facebook
2 Facebook pages
googleplus
1 Google+ user
video
1 YouTube creator

Citations

dimensions_citation
177 Dimensions

Readers on

mendeley
320 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
The effects of short-term fasting on tolerance to (neo) adjuvant chemotherapy in HER2-negative breast cancer patients: a randomized pilot study
Published in
BMC Cancer, October 2015
DOI 10.1186/s12885-015-1663-5
Pubmed ID
Authors

Stefanie de Groot, Maaike PG Vreeswijk, Marij JP Welters, Gido Gravesteijn, Jan JWA Boei, Anouk Jochems, Daniel Houtsma, Hein Putter, Jacobus JM van der Hoeven, Johan WR Nortier, Hanno Pijl, Judith R Kroep

Abstract

Preclinical evidence shows that short-term fasting (STF) protects healthy cells against side effects of chemotherapy and makes cancer cells more vulnerable to it. This pilot study examines the feasibility of STF and its effects on tolerance of chemotherapy in a homogeneous patient group with early breast cancer (BC). Eligible patients had HER2-negative, stage II/III BC. Women receiving (neo)-adjuvant TAC (docetaxel/doxorubicin/cyclophosphamide) were randomized to fast 24 h before and after commencing chemotherapy, or to eat according to the guidelines for healthy nutrition. Toxicity in the two groups was compared. Chemotherapy-induced DNA damage in peripheral blood mononuclear cells (PBMCs) was quantified by the level of γ-H2AX analyzed by flow cytometry. Thirteen patients were included of whom seven were randomized to the STF arm. STF was well tolerated. Mean erythrocyte- and thrombocyte counts 7 days post-chemotherapy were significantly higher (P = 0.007, 95 % CI 0.106-0.638 and P = 0.00007, 95 % CI 38.7-104, respectively) in the STF group compared to the non-STF group. Non-hematological toxicity did not differ between the groups. Levels of γ-H2AX were significantly increased 30 min post-chemotherapy in CD45 + CD3- cells in non-STF, but not in STF patients. STF during chemotherapy was well tolerated and reduced hematological toxicity of TAC in HER2-negative BC patients. Moreover, STF may reduce a transient increase in, and/or induce a faster recovery of DNA damage in PBMCs after chemotherapy. Larger studies, investigating a longer fasting period, are required to generate more insight into the possible benefits of STF during chemotherapy. ClinicalTrials.gov: NCT01304251 , March 2011.

X Demographics

X Demographics

The data shown below were collected from the profiles of 26 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 320 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 320 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 62 19%
Student > Master 39 12%
Researcher 31 10%
Other 28 9%
Student > Ph. D. Student 23 7%
Other 48 15%
Unknown 89 28%
Readers by discipline Count As %
Medicine and Dentistry 83 26%
Nursing and Health Professions 42 13%
Biochemistry, Genetics and Molecular Biology 29 9%
Agricultural and Biological Sciences 18 6%
Immunology and Microbiology 6 2%
Other 41 13%
Unknown 101 32%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 100. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 18 March 2023.
All research outputs
#426,034
of 25,507,011 outputs
Outputs from BMC Cancer
#42
of 9,009 outputs
Outputs of similar age
#5,926
of 289,934 outputs
Outputs of similar age from BMC Cancer
#4
of 237 outputs
Altmetric has tracked 25,507,011 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 98th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 9,009 research outputs from this source. They receive a mean Attention Score of 4.7. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 289,934 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 97% of its contemporaries.
We're also able to compare this research output to 237 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 98% of its contemporaries.